

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number 09/693,754
				Filing Date 2000-10-20
				First Named Inventor N. Berinstein
				Art Unit 1633
				Examiner Name Anne Marie Sabrina Wehbe
Sheet	1	of	3	Attorney Docket No: 13115

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A1	5,093,258		1992-03-03	Cohen, et al.	Entire document
A2	5,141,742		1992-08-05	Brown, et al.	Entire document
A3	5,342,774		1994-08-30	Boon, et al.	Entire document
A4	5,405,940		1995-04-11	Boon, et al.	Entire document
A5	5,462,871		1995-10-31	Boon-Faulier, et al.	Entire document
A6	5,505,941		1996-04-09	Paoletti, E.	Entire document
A7	5,831,016		1998-11-03	Wang, et al.	Entire document
A8	5,840,839		1998-11-24	Wang, et al.	Entire document
A9	5,844,075		1998-12-01	Kawakami, et al.	Entire document
A10	5,874,560		1999-02-23	Kawakami, et al.	Entire document
A11	5,972,597		1999-10-26	Paoletti, et al.	Entire document
A12	6,001,349		1999-12-14	Panicali, et al.	Entire document
A13	6,045,802		2000-04-04	Schlom, et al.	Entire document
A14	6,083,703		2000-07-04	Wang, et al.	Entire document
A15	6,087,110		2000-07-11	Wang, et al.	Entire document
A16	6,127,116		2000-10-03	Rice, et al.	Entire document
A17	6,132,980		2000-10-17	Wang, et al.	Entire document
A18	6,319,496		2001-11-20	Panicah, et al.	Entire document
A19	6,340,462		2002-01-22	Paoletti, et al.	Entire document
A20	6,407,063		2002-06-18	Luiten, et al.	Entire document
A21	6,531,451		2003-03-11	Chaux, et al.	Entire document
A22	6,548,068		2003-04-15	Schlom, et al.	Entire document
A23	6,558,671		2003-05-06	Shingluff, et al.	Entire document
A24	6,693,086		2004-02-17	Dow, et al.	Entire document
A25	6,699,475		2003-05-06	Slingluff, et al.	Entire document
A26	6,756,038		2004-06-29	Schlom, et al.	Entire document
A27	6,780,407		2004-08-24	Paoletti, et al.	Entire document
A28	6,710,172		2004-03-23	Chaux, et al.	Entire document
A29	6,805,869		2004-10-19	Guo, Y.	Entire document
A30	6,893,869		2005-05-17	Schlom, et al.	Entire document
A31	6,951,917		2005-10-04	Topalian, et al.	Entire document
A32	6,969,609		2005-11-29	Schlom, et al.	Entire document
A33	7,232,887		2007-06-19	Kawakami, et al.	Entire document
A34	2003/0082150		2003-05-01	Boon-Faulier, et al.	Entire document

EXAMINER**DATE CONSIDERED**

Supplementary Disclosure Statement System (SDSS) - 6400

* EXAMINER: Initial if reference considered. "X" other if not relevant or is in conformance with MPEP 608. Draw a line through citation if not in conformance and not considered. Handwrite easily of this item with next continuation line to applicant. * Applicant's unique citation designation number (sequential); Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (11/10/2009)

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/693,754
				Filing Date	2000-10-20
				First Named Inventor	N. Bernstein
				Art Unit	1633
				Examiner Name	Anne Marie Sabrina Wehbe
				(Use as many sheets as necessary)	
Sheet	2	of	3	Attorney Docket No: 13115	

US PATENT DOCUMENTS

Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
A35	2004/0156861A1		2004-08-12	Figdor, et al.	Entire document
A36	2005/0136066A1		2005-06-23	Guo, Y.	Entire document
A37	09/693,755		N/A	Bernstein, et al.	Entire document

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
B1	WO 96/11279	1995-10-02	The Govt. USA		Entire document	
B2	WO 99/40188	1999-08-12	Cabezon, et al.		Entire document	
B3	WO 99/46992	1999-09-23	Kaplan, et al.		Entire document	
B4	WO 01/30847	2001-05-03	Aventis Pasteur Limited		Entire document	

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ³	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
C1	COX, et al. Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines. <i>Science</i> , vol. 264: 716-719 (1994)		
C2	HODGE, et al. Diversified Prime and Boost Protocols Using Recombinant Vaccine Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses. <i>Vaccine</i> , vol. 15, issue 6/7, pp. (1997)		
C3	HURPIN, et al. The Mode of Presentation and Route of Administration Are Critical for the Induction of Immune Responses to p53 and Antitumor Immunity. <i>Vaccine</i> , vol. 16, no. 2/3, pp. 208-215 (1998)		
C4	IRVINE, et al. Recombinant Virus Vaccination Against "Self" Antigens Using Anchor-Fixed Immunogens. <i>Cancer Res.</i> , vol. 59: 2536-2540 (1999)		
C5	KAWAKAMI, et al. Identification of a Human Melanoma Antigen Recognized by Tumor-Infiltrating Lymphocytes Associated with <i>in vivo</i> Tumor Rejection. <i>Proc. Natl. Acad. Sci. USA</i> , vol. 91, pp. 6458-6462 (1994)		
C6	KUNDIG, et al. Fibroblasts as Efficient Antigen-Presenting Cells in Lymphoid Organs. <i>Science</i> , vol. 268, pp. 1343-1347 (1995)		

EXAMINER**DATE CONSIDERED**

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number 09/693,754
				Filing Date 2000-10-20
				First Named Inventor N. Berinstein
				Art Unit 1633
				Examiner Name Anne Marie Sabrina Wehbe
Sheet	3	of	3	Attorney Docket No: 13115

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ³	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C7	LEHNER, et al. Targeted Lymph Node Immunization with Simian Immuno deficiency Virus p27 Antigen to Elicit Genital, Rectal, and Urinary Immune Responses in Nonhuman Primates. <i>J. Immunol.</i> Vol. 153: 1858-1868 (1994)		T*
	C8	LEHNER, et al. Protective Mucosal Immunity Elicited by Targeted Iliac Lymph Node Immunization with a Subunit SIV Envelope and Core Vaccine in Macaques. <i>Nat. Med.</i> Vol. 2, No. 7, pp. 767-775 (1996)		
	C9	LEHNER, et al. The Effect of Route of Immunization on Mucosal Immunity. <i>J. Infect. Dis.</i> 179(suppl. 3), pp. S489-S492 (1999)		
	C10	MACKENSEN, et al. Homing of Intravenously and Intra lymphatically Injected Human Dendritic Cells Generated in vitro from CD34+ Hematopoietic Progenitor Cells. <i>Cancer Immunol. Immunother.</i> Vol. 48, pp. 118-122 (1999)		
	C11	NESTLE, et al. Vaccination of Melanoma Patients with Peptide- or Tumor Lysate-Pulsed Dendritic Cells. <i>Nature Med.</i> Vol. 4, No. 3, pp. 328-332 (1998)		
	C12	PARKHURST, et al. Improved Induction of Melanoma-Reactive CTL with Peptides from Melanoma Antigen gp100 Modified at HLA-A0201-Binding Residues. <i>J. Immunol.</i> Vol. 157, no. 6, pp. 2539-48 (1996)		
	C13	POND, et al. Interactions Between Adipose Tissue Around Lymph Nodes and Lymphoid Cells in vitro. <i>Vol. 36</i> , pp. 2219-2231 (1995)		
	C14	PUNT, et al. Biodistribution and Vaccine Efficiency of Murine Dendritic Cells are Dependent on the Route of Administration. <i>Cancer Res.</i> Vol. 59, pp. 3340-3345 (1999)		
	C15	RAO, et al. Partial Characterization of Two Subpopulations of T4 Cells Induced by Active Specific Intra lymphatic Immunotherapy (ASILI) in Melanoma Patients. <i>Vol. 27</i> , abstract 1290 (1986)		
	C16	RESTIFO, et al. Antigen Processing In Vivo and the Elicitation of Primary CTL Responses. <i>J. Immunol.</i> 154: 4414-4422 (1995)		
	C17	SALGALLER, et al. Immunization Against Epitopes in the Human Melanoma Antigen gp100 Following Patient Immunization with Synthetic Peptides. <i>Cancer Res.</i> Vol. 56, pp. 4749-4757 (1996)		
	C18	WIRA, et al. Effect of Uterine Immunization and Oestradiol on Specific IgA and IgG Antibodies in Uterine, Vaginal and Salivary Secretions. <i>Immunology</i> , vol. 68, pp. 24-30 (1989)		
	C19	WIRA, et al. Specific IgA and IgG Antibodies in the Secretions of the Female Reproductive Tract: Effects of Immunization and Estradiol on Expression of this Response In vitro. <i>J. Immunol.</i> Vol. 138, No. 12, pp. 4159-4164 (1987)		
	C20	WOLFEL, et al. Two Tyrosine Nonpeptides Recognized on HLA-A2 Melanomas by Autologous Cytolytic T Lymphocytes. <i>Eur. J. Immunol.</i> Vol. 24, pp. 759-764 (1994)		

EXAMINER**DATE CONSIDERED**

Examiner Disclosure Statement Form (PTO-1449)
• EXAMINER: Initial if reference considered, "X" mark if not taken as in conformance with 35 U.S.C. 102(b). Draw line through citation if not in conformance and not considered. Handwrite copy of this form with next conformance to applicant's language when foreign number is present. If applicable, place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (11/10/2009)

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/693,754
				Filing Date	2000-10-20
				First Named Inventor	N. Berinstein
				Art Unit	1633
				Examiner Name	Anne Marie Sabrina Wehbe
Sheet	4	of	3	Attorney Docket No: 13115	

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ³	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C21	XIANG, et al. An Autologous Oral DNA Vaccine Protects Against Murine Melanoma. Proc. Natl. Acad. Sci. USA, vol. 97, no. 10, pp. 5492-5497 (2000)	
	C22	ZAREMBA, et al. Identification of an Enhancer Agonist Cytotoxic T Lymphocyte Peptide from Human Carcinoembryonic Antigen. Cancer Res. Vo. 57, pp. 4570-4577 (1997)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (11/10/2009)

EXAMINER /Anne Marie Wehbe/ (11/10/2009)**DATE CONSIDERED**

11/10/2009